Bladder Cancer
Conditions
Brief summary
Early detection of bladder cancer (BCa) is considered an effective strategy to curb mortality from the disease. However, current urinary biomarkers have insufficient specificity to warrant BCa screening. Urine free glycosaminoglycan profiles (or GAGomes) are promising noninvasive biomarkers of cancer metabolism. In this study, samples are obtained from patients with BCa and controls to compare the glycosaminoglycan profiles between groups.
Interventions
DIAGNOSTIC_TESTFree glycosaminoglycan profiling
Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.
Sponsors
Göteborg University
Jens Nielsen
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
Cases (Bladder cancer \[BCa\]) Inclusion Criteria: * Primary BCa diagnosis at cystoscopy, planned for TURB
Exclusion criteria
* No histopathological diagnosis of BCaTa-T4 N0-2 MX-0 after TURB Controls (No evidence of disease \[NED\]) Inclusion Criteria: * In follow-up with cystoscopy after treatment Ta-T3 N0-2 M0 BCa or upper tract urothelial cancer no evidence of disease at cystoscopy for at least 6 months prior to inclusion * No history of cancer except urothelial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area-under-the-receiving operating characteristic (ROC)-curve (AUC) for the classification of BCa versus NED | Before primary surgery for BCa; at a post-surgical follow-up visit for controls up to 5 years from primary surgery |
Countries
Sweden
Outcome results
None listed